Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
J Cancer Surviv ; 13(4): 547-557, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31250352

RESUMO

PURPOSE: Few studies have compared follow-up-care models for adult survivors of childhood cancer (ASCCs), though choice of model could impact medical test adherence, and health-related quality of life (QOL). This study compared two follow-up-care models, cancer-center-based versus community-based, for ASCCs in Alberta, Canada, to determine which model would demonstrate greater ASCC adherence to guideline-recommended medical screening tests for late effects, QOL, physical symptoms, and adherence to yearly follow-up. METHODS: ASCC discharged to a community model (over 15 years) and those with comparable birth years (1973-1993) currently followed in a cancer center model were recruited via direct contact or multimedia campaign. Chart review identified chemotherapeutic and radiation exposures, and required medical late effect screening tests. ASCCs also completed questionnaires assessing QOL, physical symptoms, and follow-up behavior. RESULTS: One hundred fifty-six survivors participated (community (n = 86); cancer center (n = 70)). Primary analysis indicated that cancer center ASCCs guideline-recommended total test adherence percentage (Mdn = 85.4%) was significantly higher than the community model (Mdn = 29.2%, U = 3996.50, p < 0.0001). There was no significant difference in QOL for cancer center ASCCs (M = 83.85, SD = 20.55 versus M = 77.50, SD = 23.94; t (154) = 1.77, p = 0.078) compared to community-based ASCCs. Cancer center-based ASCCs endorsed from 0.4-7.1% fewer physical symptom clusters, and higher adherence to follow-up behavior in comparisons using effect sizes without p values. CONCLUSION: This study highlights the cancer center model's superiority for adherence to exposure-based medical late effect screening guidelines, cancer-specific follow-up behaviors, and the reporting of fewer physical complaints in ASCCs. IMPLICATIONS FOR CANCER SURVIVORS: ASCCs followed in a cancer center model likely benefit from earlier late-effects detection and opportunities for early intervention.


Assuntos
Assistência ao Convalescente/organização & administração , Sobreviventes de Câncer , Modelos Organizacionais , Neoplasias/terapia , Adolescente , Adulto , Assistência ao Convalescente/normas , Canadá/epidemiologia , Sobreviventes de Câncer/estatística & dados numéricos , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Neoplasias/patologia , Cooperação do Paciente/estatística & dados numéricos , Qualidade de Vida , Inquéritos e Questionários
2.
J Thromb Haemost ; 6(4): 589-94, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18194413

RESUMO

BACKGROUND: Deep vein thrombosis (DVT) is a complication of treatment of acute lymphoblastic leukemia (ALL) in children but little is known about the long-term outcomes of these DVT. OBJECTIVE: To determine the incidence of post-thrombotic syndrome (PTS) in (i) children with ALL diagnosed with asymptomatic DVT using radiographic testing and (ii) an unselected group of ALL survivors. METHODS: Cross-sectional study in two populations. Group I comprised children in the Prophylactic Antithrombin Replacement in Kids with ALL treated with L-Asparaginase (PARKAA) study diagnosed with DVT by radiographic tests. Group II consisted of non-selected childhood ALL survivors <21 years. PTS was assessed using a standardized scoring sheet. RESULTS: Group I: 13 PARKAA patients (median age 12 years) were assessed, and 7 had PTS (54%; 95% CI, 25-81). All patients had collaterals, three also had increased arm circumference. Group II: 41 patients (median age 13 years) with a history of ALL were enrolled, and 10 had PTS (24%; 95% CI, 11-38). All patients had collaterals; five also had increased arm circumference. CONCLUSION: There is a high incidence of PTS in survivors of childhood ALL with radiographically diagnosed asymptomatic DVT. A significant proportion of ALL survivors develop PTS, indicating previously undiagnosed DVT.


Assuntos
Síndrome Pós-Trombótica/epidemiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Trombose Venosa/complicações , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Deficiência de Antitrombina III/induzido quimicamente , Braço/irrigação sanguínea , Braço/patologia , Asparaginase/administração & dosagem , Asparaginase/efeitos adversos , Cateterismo Venoso Central/efeitos adversos , Criança , Pré-Escolar , Ensaios Clínicos Fase II como Assunto/estatística & dados numéricos , Circulação Colateral , Estudos Transversais , Feminino , Seguimentos , Humanos , Incidência , Masculino , Estudos Multicêntricos como Assunto/estatística & dados numéricos , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue , Prevalência , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Sobreviventes , Trombofilia/induzido quimicamente , Trombose Venosa/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA